Targeted nanomedicine reduces vascular lesions in mouse models
The new nanoparticle uses a peptide to target the vascular cell adhesion molecule 1 and reduced the size of vascular lesions in a mouse study.
List view / Grid view
The new nanoparticle uses a peptide to target the vascular cell adhesion molecule 1 and reduced the size of vascular lesions in a mouse study.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
The exciting new study demonstrates how the technology could be used to improve animal welfare in scientific research and agriculture.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
Transformational machine learning (TML) learns from multiple problems and improves performance while it learns, potentially accelerating drug discovery.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
The new study used cryo-electron microscopy to visualise the structure of a HAT protein and uncover compounds for drug development.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.